ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset

References

• Sherr J, Sosenko J, Skyler JS, Herold KC. Prevention of type 1 diabetes: The time has come. Nat Clin Pract Endocrinol Metab. 2008; 4:334–343.
   PubMedGoogle Scholar
• Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity. 2008; 41:11–18.
   PubMed Web of Science ®Google Scholar
• Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA. 2007; 104:17040–17045.
   PubMed Web of Science ®Google Scholar
• Wenzlau JM, Moua O, Sarkar SA, Yu L, Rewers M, Eisenbarth GS, Davidson HW, Hutton JC. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann NY Acad Sci. 2008; 1150:256–259.
   PubMedGoogle Scholar
• Seve M, Chimienti F, Devergnas S, Favier A. In silico identification and expression of SLC30 family genes: An expressed sequence tag data mining strategy for the characterization of zinc transporters' tissue expression. BMC Genomics. 2004; 5:32.
   PubMedGoogle Scholar
• Wenzlau JM, Moua O, Liu Y, Eisenbarth GS, Hutton JC, Davidson HW. Identification of a major humoral epitope in Slc30A8 (ZnT8). Ann NY Acad Sci. 2008; 1150:252–255.
   PubMed Web of Science ®Google Scholar
• Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshezhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007; 445:881–885.
   PubMed Web of Science ®Google Scholar
• Wenzlau JM, Frisch LM, Gardner TJ, Sarkar S, Hutton JC, Davidson HW. Novel antigens in type 1 diabetes: The importance of ZnT8. Curr Diab Rep. 2009; 9:105–112.
   PubMed Web of Science ®Google Scholar
• Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S, Walters J, Eisenbarth GS, Davidson HW, Hutton JC. A common non-synonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes. 2008; 57:2693–2697.
   PubMed Web of Science ®Google Scholar
• Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H, Winkler C, Pfluger M, Illig T, Bonifacio E, Ziegler AG. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia. 2009; 52:1881–1888.
   PubMed Web of Science ®Google Scholar
• Törn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohme G, Lithner F, Littorin B, Nystrom L, Schersten B, Sundkvist G, Wibell L, Östman J. Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab. 2000; 85:4619–4623.
   PubMedGoogle Scholar
• Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M, Harris RA, Robertson JA, Lernmark A. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Compl. 2005; 19:238–246.
   PubMed Web of Science ®Google Scholar
• Hampe CS, Hammerle LP, Bekris L, Ortqvist E, Kockum I, Rolandsson O, Landin-Olsson M, Torn C, Persson B, Lernmark A. Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes. J Clin Endocrinol Metab. 2000; 85:4671–4679.
   PubMed Web of Science ®Google Scholar
• Mire-Sluis AR, Das RG, Lernmark Å. The World Health Organization international collaborative study for islet cell antibodies. Diabetologia. 2000; 43:1282–1292.
   PubMed Web of Science ®Google Scholar
• Oak S, Phan TH, Gilliam LK, Hirsch IB, Hampe CS. Animal insulin therapy induces a biased insulin antibody response that persists for years after introduction of human insulin. Acta Diabetol. 2009[ublishonle].
   PubMedGoogle Scholar
• Bingley PJ, Bonifacio E, Mueller PW. Diabetes antibody standardization program: First assay proficiency evaluation. Diabetes. 2003; 52:1128–1136.
   PubMed Web of Science ®Google Scholar
• Graham J, Hagopian WA, Kockum I, Li LS, Sanjeevi CB, Lowe RM, Schaefer JB, Zarghami M, Day HL, Landin-Olsson M, Palmer JP, Janer-Villanueva M, Hood L, Sundkvist G, Lernmark A, Breslow N, Dahlquist G, Blohmé G. Diabetes Incidence in Sweden Study Group; Swedish Childhood Diabetes Study Group. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes. 2002; 51:1346–1355.
   PubMed Web of Science ®Google Scholar
• Borg H, Gottsater A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes. 2002; 51:1754–1762.
   PubMedGoogle Scholar
• Decochez K, Tits J, Coolens JL, Van Gaal L, Krzentowski G, Winnock F, Anckaert E, Weets I, Pipeleers DG, Gorus FK. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. Diabetes Care. 2000; 23:838–844.
   PubMed Web of Science ®Google Scholar
• Jensen RA, Gilliam LK, Törn C, Landin-Olsson M, Karlsson FA, Palmer JP, Kockum I, Akesson K, Lernmark B, Lynch K, Breslow N, Lernmark A. Diabetes Incidence Study in Sweden (DISS) group. Multiple factors affect the loss of measurable Cpeptide over 6 years in newly diagnosed 15- to 35-year-old diabetic subjects. J Diabetes Compl. 2007; 21:205–213.
   PubMedGoogle Scholar
• Borg H, Marcus C, Sjoblad S, Fernlund P, Sundkvist G. Islet cell antibody frequency differs from that of glutamic acid decarboxylase antibodies/IA2 antibodies after diagnosis of diabetes. Acta Paediatr. 2000; 89:46–51.
   PubMedGoogle Scholar
• Savola K, Sabbah E, Kulmala P, Vahasalo P, Ilonen J, Knip M. Autoantibodies associated with type I diabetes mellitus persist after diagnosis in children. Diabetologia. 1998; 41:1293–1297.
   PubMed Web of Science ®Google Scholar
• Oak S, Gilliam LK, Landin-Olsson M, Torn C, Kockum I, Pennington CR, Rowley MJ, Christie MR, Banga JP, Hampe CS. The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci USA. 2008; 105:5471–5476.
   PubMed Web of Science ®Google Scholar
• Nayak R, Mitra-Kaushik S, Shaila MS. Perpetuation of immunological memory: A relay hypothesis. Immunology. 2001; 102:387–395.
   PubMedGoogle Scholar
• Tillakaratne NJ, Erlander MG, Collard MW, Greif KF, Robin AJ. Glutamate decarboxylases in nonneural cells of rat testis and oviduct: Differential expression of GAD65 and GAD67. J Neurochem. 1992; 58:618–627.
   PubMedGoogle Scholar
• Takeyama N, Ano Y, Wu G, Kubota N, Saeki K, Sakudo A, Momotani E, Sugiura K, Yukawa M, Onodera T. Localization of insulinoma associated protein 2, IA-2 in mouse neuroendocrine tissues using two novel monoclonal antibodies. Life Sci. 2009; 84:67–6878.
   Google Scholar
• Gyulkhandanyan AV, Lu H, Lee SC, Bhattacharjee A, Wijesekara N, Fox JE, MacDonald PE, Chimienti F, Dai FF, Wheeler MB. Investigation of transport mechanisms and regulation of intracellular Zn2+ in pancreatic alpha-cells. J Biol Chem. 2008; 283:10184–10197.
   PubMed Web of Science ®Google Scholar
• Chimienti F, Devergnas S, Favier A, Seve M. Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes. 2004; 53:2330–2337.
   PubMed Web of Science ®Google Scholar
• Gillard P, Vandemeulebroucke E, Keymeulen B, Pirenne J, Maes B, De Pauw P, Vanrenterghem Y, Pipeleers D, Mathieu C. Functional beta-cell mass and insulin sensitivity is decreased in insulin-independent pancreas-kidney recipients. Transplantation. 2009; 87:402–407.
   PubMed Web of Science ®Google Scholar
• Bach JF, Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol. 2001; 19:131–161.
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R.. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008; 359:1909–1920.
   PubMed Web of Science ®Google Scholar
• Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The diabetes prevention trial-type 1. Diabetes Care. 2005; 28:1068–1076.
   PubMed Web of Science ®Google Scholar